Epstein-Barr virus (EBV)-based gene delivery vectors that preferentially express toxic genes in EBV-infected cells could be used to target EBV-positive tumors for destruction. We have shown previously that the cytosine deaminase (CD) enzyme, which converts the prodrug 5-fluorocytosine (5-FC) into the toxic compound 5-fluorouracil efficiently kills EBV-positive cells in the presence of 5-FC, with a substantial bystander killing effect in vitro and in vivo. To identify the optimal enzyme/prodrug combination for treating EBV-positive lymphomas, we have compared the effectiveness of the CD/5-FC combination with the nitroreductase (NTR)/CB1954 combination for killing EBV-positive B-cell lines. NTR metabolizes CB1954 into an alkylating agent that cross-links DNA. When the CD gene or the NTR gene were transfected into two different EBV-positive B-cell lines in vitro, ϳ90% of cells were killed in a prodrug-dependent manner, although the transfection efficiency was Ͻ5%. However, severe combined immunodeficient mouse tumors containing either 30% or 100% of NTR-expressing Burkitt lymphoma (Jijoye) cells were growth inhibited, but not cured, by treatment with intraperitoneal CB1954 (20 mg/kg/day) for 10 days. These results suggest that the NTR/CB1954 combination induces efficient bystander killing of EBV-positive B-cell lines in vitro but may not be as effective as the CD/5-FC combination for treating B-cell lymphomas in vivo. Cancer Gene Therapy (2000) 7, 97-106
pstein-Barr virus (EBV), a human herpesvirus, causes infectious mononucleosis in the immunocompetent host and is associated with a variety of different tumor types. 1 The EBV genome is frequently present in lymphoproliferative disorders of immunocompromised patients [1] [2] [3] and in Յ100% of primary central nervous system lymphomas of AIDS patients. 4 EBV is also found in almost all cases of undifferentiated nasopharyngeal carcinoma, 5 in Hodgkin's disease, 6 in some gastric carcinomas, 7 and in leiomyosarcomas of immunocompromised hosts. 8, 9 The presence of EBV in tumor cells could potentially be used to target EBV-associated malignancies for destruction by placing suicide genes under the direction of EBV-specific promoter and/or replication elements. 10 -14 Recently, we constructed two different EBV-based gene delivery vectors and demonstrated that genes in these vectors are expressed at a much higher level in EBVpositive cells versus EBV-negative cells.
11 EBV-dependent replication increased the copy number of these vectors in EBV-positive lymphoma cells (using either the latent (oriP), or lytic, origins of EBV replication), and an EBV-dependent enhancer element also increased the transcription of genes delivered through these vectors. In addition, EBV-encoded nuclear antigen-1 (EBNA-1) has been shown recently to increase nuclear transport of origin of oriP-containing plasmids. 15 Thus, it should be possible to express cellular toxins in an EBV-dependent fashion. Nevertheless, given the inefficiency of currently available methods for in vivo gene delivery, it is preferable to use a gene toxin that not only kills tumor cells expressing the gene toxin but also kills nearby tumor cells in which the gene was not delivered (the so-called "bystander" killing effect). 16 -19 Bystander killing was originally described with the herpes simplex virus thymidine kinase (HSV-TK)/ganciclovir (GCV) combination. 16, 17, 19 When the HSV-TK gene is delivered to only a portion of cells, in some cell types GCV (which is phosphorylated by HSV-TK into a cytotoxic agent that inhibits the cellular DNA polymerase) kills the entire cell population. 16 -18 The bystander killing induced by the HSV-TK/GCV combination is cell type-specific 10, 20 and may be mediated by the transfer of phosphorylated GCV from cell to cell through gap junctions or apoptotic vescicles. 16, 19 The combination of the cytosine deaminase (CD) gene with 5-fluorocytosine (5-FC) also exhibits strong bystander killing. 10, 21, 22 CD converts 5-FC into the toxic compound 5-fluorouracil. 21 ,23 5-fluorouracil is readily diffusible and can thus be taken up by nearby cells not expressing the CD gene. 21 To identify the most potent suicide gene/prodrug combination for killing EBV-associated lymphomas, we previously compared the efficiency of the HSV-TK/GCV combination with the CD/5-FC regimen for killing EBVtransformed lymphoblastoid B-cell lines in vitro and in vivo. 10 Although both regimens efficiently induced the killing of EBV-positive lymphoblastoid cells expressing the suicide gene, only the CD/5-FC combination was found to induce bystander killing of EBV-positive B cells in vitro. 10 Nevertheless, the HSV-TK/GCV combination did induce significant bystander killing of EBV-positive lymphomas in severe combined immunodeficient (SCID) mice (although the CD/5-FC combination was still superior in vivo). The observed bystander killing of B cells with the HSV-TK/GCV combination in vivo, but not in vitro, suggests that additional mechanisms (perhaps immune-mediated) may promote lymphoma cell killing in vivo that cannot be studied in vitro.
A potential limitation to both the HSV-TK/GCV and CD/5-FC combinations is that the toxicity of nucleoside analogs is restricted to proliferating cells. 23 For maximal antitumor therapy, the mechanism of cell killing should preferably be independent from the cell cycle stage of the tumor cell. This is the case for a recently described suicide gene/prodrug combination, nitroreductase (NTR)/ CB1954. 24 NTR converts the monofunctional alkylating agent, CB1954 ([5-aziridin-1-yl]Ϫ2,4 dinitrobenzamide), into a toxic form by reducing the 4-nitro group of CB1954, resulting in a difunctional alkylating agent, 5-aziridin-1-yl-4-hydroxylamino-2-nitrobenzamide. 25 The CB1954/NTR combination has recently been used for tumor cell killing in vitro 24,26 -28 and has been shown to have a bystander killing effect in several different tumor types in vitro. 26 -29 Expression of the NTR gene under the control of tissue-specific promoters in transgenic mice was followed by selective elimination of the cell types in which NTR was expressed in the presence of systemic CB1954 administration. 27, 28 However, there are no reports on the efficacy of the CB1954/ NTR combination in B cells in vitro or in vivo.
In the study presented here, we show that CB1954 has a bystander killing effect on lymphoma cells in vitro that is comparable with the CD/5-FC combination. We also show that tumors established from NTR-transduced human EBV-positive Burkitt lymphoma cells in SCID mice are reduced during systemic CB1954 administration. The presence of 30% of cells stably expressing NTR in these tumors is sufficient to produce a bystander effect in vivo, although not to the same extent as we have shown previously using the CD/5-FC combination. 10 This is the first study to examine the effect of the NTR/CB1954 combination in lymphoma cells in vitro and in vivo.
MATERIALS AND METHODS

Cell lines
B95-8 is an EBV-positive marmoset B-cell line. Jijoye (EBVpositive) and DG75 (EBV-negative) are human Burkitt lymphoma cell lines. All lymphoid cell types were maintained in RPMI 1640 medium with 10% fetal bovine serum and penicillin/streptomycin.
Construction of plasmid vectors
The pREP9 vector (Invitrogen, San Diego, Calif), which contains the intact EBV oriP as well as the EBV EBNA-1 gene, was cut with the restriction enzymes StuI and ClaI and religated to remove the DNA sequences between 5470 and 7445 and to thereby inactivate the EBNA-1 gene. The Escherichia coli NTR gene was isolated as a 0.7-kilobase HindIII-BamHI fragment from the plasmid CMV-NTR and cloned into the HindIII/BamHI cut modified pREP9 vector under the control of the Rous sarcoma virus (RSV) promoter ( Fig 1A) . This resulted in the plasmid pREP9-NTR. The plasmid pREP9-CD (Fig 1B) was constructed in a similar way by ligating a 1.5-kilobase HindIII-BamHI fragment spanning the E. coli CD gene into the EBNA-1-deleted pREP9 vector. The CD gene was isolated from the CMV-CD plasmid (a gift of Brian Huber, Glaxo-Wellcome, Research Triangle Park, NC). The pREP9-LacZ vector was constructed by cloning the bacterial ␤-galactosidase (␤-gal) fragment from the pSV2-␤-gal vector (Promega, Madison, Wis) into the modified pREP9 vector.
Transfection of vector DNA and selection of stable cell lines DNA from the pREP9-based plasmids described above was purified by passing through Qiagen columns as recommended by the manufacturer (Qiagen, Chatsworth, Calif). Jijoye and B95-8 cells were transfected with 10 g of each plasmid by electroporation with a Zapper electroporation unit (Medical Electronics Shop, University of Wisconsin, Madison, Wis) at 1500 V. To establish stable cell lines, 500 g/mL G418 was added 3 days after electroporation. Cell lines were selected from pools of G418-resistant cells.
␤-gal assays
Transfected cells were washed in phosphate-buffered saline (PBS) and subsequently fixed in 0.5% glutaraldehyde for 10 minutes on day 1 posttransfection. ␤-gal staining was performed as suggested by the manufacturer (Promega).
In vitro cytotoxicity assays
A total of 5 ϫ 10 5 cells were plated into a well of a 24-well dish and incubated in 1 mL of medium with varying prodrug concentrations. CB1954 was a gift from Glaxo-Wellcome. On day 3, 0.5 mL of fresh medium was added to each well. Viable cells were counted by trypan blue exclusion on day 7 after addition of the prodrugs. To determine the bystander killing effects, untransfected control cells were mixed with increasing amounts of stably transduced pREP9-NTR or pREP9-CD cells and cytotoxicity tests were performed in the presence of prodrug as described above. All of the results shown were obtained in at least two independent experiments.
NTR enzyme assays
NTR assays were essentially performed as described previously, 30 with the following modifications: after washing with PBS, cell pellets were resuspended in PBS containing 1% Nonidet P-40 and protease inhibitors and incubated in ice for 30 minutes. Cytoplasmic extracts were obtained after centrifugation of the lysates at 4°C and quantified by using the Bio-Rad protein assay (Hercules, Calif). The final reaction mixture (1 mL) of the NTR assay contained 500 mol of menadione as substrate, 500 mol of reduced nicotinamide-adenine dinucleotide, and 70 mol of cytochrome c as the terminal electron acceptor in 10 mmol of tris(hydroxymethyl)aminomethaneHCl (pH 7.5). Immediately before starting each individual reaction, the reaction components were mixed and prewarmed for 1 minute at 37°C in the dark. Next, 40 g of protein was added and the linear increase in absorption at 550 nm due to reduction of cytochrome c was monitored over 90 seconds at 37°C. NTR enzyme activity was calculated as the amount of reduced cytochrome c per 90 seconds per 40 g of protein.
In vivo tumor studies
We subcutaneously injected 4-to 5-week-old SCID mice (NIH) with 5 ϫ 10 7 log phase Jijoye cells in both flanks. Jijoye cells consisted of either 100% untransfected cells, 100% Jijoye cells stably transduced with the pREP9-NTR vector, or a mixture of 30% Jijoye cells transduced with the pREP9-NTR vector and 70% untransfected cells. When tumors became palpable ϳ10 days later, CB1954 treatment (intraperitoneal (i.p.) injections of 20 mg/kg daily) were begun and continued for 10 days. Tumor volumes were measured for 48 days after the initial tumor cell injections. Two perpendicular tumor diameters were measured using calipers, and volumes were estimated as follows: V ϭ A ϫ B 2 /2, with A equaling the largest diameter and B equaling the smallest diameter measured on the largest section of the tumor. Mice were sacrificed when tumors became extremely large (Ͼ1 cm) or when the animals appeared ill.
RESULTS
CB1954 induces killing in EBV-positive cell lines transfected with an oriP-based NTR expressing plasmid
To examine the NTR/CB1954-induced killing of EBVpositive B cells, the bacterial NTR gene was cloned into an EBNA-1-deleted version of the commercially available plasmid pREP9 under the control of the RSV promoter (Fig 1) . The modified pREP9 construct requires the EBV protein EBNA-1 (present in all EBVinfected cells) in trans for oriP-mediated episomal replication and is thus specifically amplified in EBV-positive cells. The bacterial CD gene and the bacterial lacZ gene were also cloned into the EBNA-1-deleted pREP9 vector as positive and negative controls, respectively.
The pREP9-NTR and pREP9-LacZ vectors were transfected into two EBV-positive B-cell lines, B95-8 and Jijoye, and into DG75, an EBV-negative human Burkitt lymphoma line. ␤-gal staining was performed on day 1 posttransfection to determine the initial transfection efficiency and was similar in all three cell lines (ϳ2% of cells transfected). pREP9-NTR (or pREP9-LacZ) transfected cells were incubated with the prodrug CB1954 (beginning 5 days after transfection). Cell viability was determined by trypan blue exclusion 7 days later.
As shown in Figure 2 , expression of the NTR gene in EBV-positive B-cell lines dramatically enhanced CB1954-induced cell killing. In Jijoye cells, many more (Ͼ10-fold) pREP9-NTR-transfected cells were killed by the 1 M and 10 M doses of CB1954 than the pREP9-LacZ-transfected cells (Fig 2A) . Similar results were obtained in the EBV- (Fig 2B) . Although the transfection efficiency of Jijoye and B95-8 cells in these experiments was Ͻ5%, many of the untransfected cells were also killed by CB1954, indicating that much of the CB1954-induced killing occurs through a bystander mechanism. As expected, pREP9-NTR-transfected EBV-negative DG75 cells had minimal CB1954-induced killing, because the oriP-mediated maintenance of the modified pREP9 vector requires EBNA-1 expression, and CB1954 was not started until 5 days posttransfection (Fig 2C) .
To compare the efficiency of the NTR/CB1954 combination with the CD/5-FC regimen for killing EBVpositive lymphomas in vitro, the CD gene (expressed in the identical vector as the NTR gene) or the pREP9-LacZ plasmids were transfected into Jijoye and B95-8 cells and treated with 5-FC starting 5 days after transfection. As shown in Figure 2 , D and E, the CD/5-FC combination (as we have reported previously using two other EBV-based vectors) 11 also induces efficient killing of EBV-positive B95-8 and Jijoye cells. Thus, the NTR/ CB1954 and CD/5-FC combinations appear to induce similar levels of killing in EBV-positive B-cell lines in vitro, although CB1954 appears to be somewhat more toxic than 5-FC to these cells in the absence of suicide gene expression.
Creation of stable EBV-positive B-cell lines expressing the NTR and CD genes To further compare the potential bystander effects of the NTR/CB1954 combination with the CD/5-FC combination in EBV-positive lymphomas, we established stable cell lines by transfecting B95-8 and Jijoye cells with the plasmids pREP9-NTR or pREP9-CD and selecting for G418 resistance. Although we easily selected Jijoye and B95-8 cell lines expressing the CD gene, even after several attempts only Jijoye cells could be stably transduced with the pREP9-NTR vector. Thus, stable expression of the NTR protein may be toxic for some B-cell lines.
Using the stably transfected cell lines, we compared NTR-and CD-expressing cells with parental cells with regard to their sensitivity to the prodrugs CB1954 and 5-FC. As shown in Figure 3A , the administration of 10 M of CB1954 was able to kill 90% of Jijoye cells stably expressing the NTR gene, but only 5% of the parental Jijoye cells. Because the parental cells required a dosage of 600 M of the CB1954 prodrug to achieve the same amount of cell killing as that induced by 10 m of CB1954 in the NTR-expressing Jijoye cells, the stable NTR-expressing cell line is 60-fold more sensitive to CB1954-induced cell killing than the parental cells.
The Jijoye and B95-8 cells stably transfected with the pREP9-CD vector were likewise examined for 5-FC sensitivity. As shown in Figure 3B To determine whether Jijoye cells stably expressing the CD and NTR genes induced bystander killing in the presence of the 5-FC and CB1954 prodrugs, we mixed parental Jijoye cells with increasing amounts of NTR-(or CD-) expressing cells and incubated them with 10 M of CB1954 or 1000 M of 5-FC (Fig 3, C and D) . In the presence of 20% Jijoye cells stably transduced with the pREP9-NTR vector, 50% of all Jijoye cells were killed. Thus, the Jijoye cells stably expressing the NTR gene retain the ability to induce bystander killing of lymphoma cells in the presence of the CB1954 prodrug, although at a reduced level in comparison with the transient transfection experiments. In contrast, the Jijoye cells stably expressing the CD gene induced bystander killing that was as efficient as that observed in the transient transfection experiments.
The reduced bystander killing observed using the stable NTR cell line could reflect decreased expression of the NTR gene in the G418-selected cells in comparison with the transient transfection experiments. NTR may be more toxic than CD for long-term expression in B-cell lines, and high level NTR expression is thus selected against (consistent with our inability to create a B95-8 line stably expressing the NTR gene). However, using a biochemical assay for NTR activity, 30 the level of NTR activity per microgram of cellular extract was slightly lower in Jijoye cells transiently transfected with the pREP9-NTR vector compared with the level in the stably selected Jijoye cells (Fig 3E) . Furthermore, the level of NTR activity achieved with our pREP9-NTR vector was similar to the level achieved using infection with a retroviral NTR vector in NIH-3T3 cells. 24 The NTR/CB1954 regimen inhibits tumor growth in vivo The creation of a stable NTR-expressing cell line allowed us to examine the effect of CB1954 on the growth of NTR-expressing lymphoma cells in vivo. SCID mice (4 to 5 weeks old) were injected in both flanks with 5 ϫ 10 7 parental Jijoye cells, 5 ϫ 10 7 Jijoye cells stably transfected with the pREP9-NTR vector, or a mixture of 30% stably transfected NTR cells and 70% of the parental line. When tumors became palpable (ϳ10 -14 days after tumor cell injection), the mice were treated for 10 days with daily i.p. injections of 20 mg/kg CB1954. Tumor sizes were estimated at various timepoints after tumor cell injection.
As shown in Figure 4 , the tumors resulting from the stably selected NTR-expressing Jijoye cell line grew much slower in the presence of the CB1954 prodrug than tumors composed entirely of the parental cell line. In the absence of prodrug, the NTR-expressing tumors grew at the same rate as the tumors composed of parental Jijoye cells (data not shown). Thus, expression of NTR in lymphoma cells clearly makes these cells more susceptible to CB1954 toxicity in vivo. At the completion of the CB1954 treatment (day 21), the presence of 30% NTR-expressing Jijoye cells reduced tumor growth by ϳ60%, suggesting that some bystander killing also occurs under in vivo conditions. However, even tumors entirely composed of the cells from the NTR-expressing cell line eventually progressed after 10 days of CB1954 treatment, in contrast to the results we obtained previously in EBV-positive lymphomas in SCID mice using the CD/5-FC or HSV-TK/GCV combinations. 10 In addition, some mice receiving CB1954 developed hair loss several weeks after completion of CB1954 treatment. The level of NTR enzyme activity was quantitated as described previously, employing menadione as a substrate and cytochrome c as the electron acceptor. 30 Extracts were prepared from Jijoye cells transiently transfected with the pREP9-LacZ or the pREP9-NTR plasmids or from Jijoye cells stably transfected with the pREP9-NTR vector ("Jijoye/pREP9-NTR"). The micromoles of reduced cytochrome c in 90 seconds per 40 g of protein extract are shown from two separate experiments for each condition. 
DISCUSSION
Although a number of gene therapy strategies have been proposed for the treatment of cancer, no human tumors have been successfully treated with this technique to date; better regimens are clearly needed. Gene delivery regimens for the treatment of human cancers are unlikely to be successful unless at minimum three criteria are met: (a) the gene delivery vectors are extremely efficient in vivo, (b) the gene delivered has a very strong bystander killing effect, and (c) cell killing is limited specifically to tumor cells. We are investigating the use of gene delivery methods for the treatment of EBVassociated malignancies because at least one of these three criteria (the ability to direct cell killing specifically to tumor cells) can be clearly met by using EBVdependent promoter and replication elements. 11 In this report, we have compared the efficiency of two different suicide gene/prodrug regimens (CD/5-FC versus NTR/ CB1954) for killing EBV-positive lymphoma cells in vitro and in vivo. Our results indicate that both regimens induce strong bystander killing of lymphoma cells in vitro, although the CD/5-FC regimen may be superior in vivo.
Previously, we compared the efficacy of the HSV-TK/ GCV and CD/5-FC regimens for killing EBV-transformed lymphoblastoid cell lines. 10 The CD/5-FC combination induced extremely efficient bystander killing of lymphoblastoid cell lines in vitro; the HSV-TK/GCV combination, although efficiently killing lymphoblastoid cells expressing the HSV-TK gene, did not induce killing of untransduced lymphoblasts in vitro. Thus, the HSV-TK/GCV combination is clearly cell type-specific in its ability to induce bystander killing in vitro and is unlikely to be as efficient as the CD/5-FC combination for treating lymphomas in vivo.
In contrast to the two most frequently used suicide gene/prodrug combinations (HSV-TK/GCV and CD/5-FC), the NTR/CB1954 combination (which results in cross-linking of DNA) can kill cells that are not actively dividing. 24 Although the ability of the NTR/CB1954 combination to kill nondividing cells may increase the efficiency of tumor growth inhibition (because many tumors contain a portion of cells that are out of cell cycle), it may also have the undesirable effect of killing normal cells. Therefore, it will be of utmost importance to compare the effectiveness and toxicity of the NTR/ CB1954 regimen with the more established regimens for treatment of various tumor types in vivo.
To directly compare the CD/5-FC and NTR/CB1954 regimens, we expressed the NTR and CD genes in the identical (EBNA-1-dependent) oriP-based vector. In transient transfection assays, both the CD/5-FC and NTR/CB1954 combinations induced extremely efficient bystander killing in EBV-positive B-cell lines, because only a small portion of the cells were transfected yet the great majority of cells were killed by each prodrug. Thus, the NTR/CB1954 regimen induces bystander killing comparable with the CD/5-FC combination in B-cell lines and is clearly more efficient than the HSV-TK/ GCV combination. In contrast to the HSV-TK/GCV combination, which requires gap junctions or apoptotic vesicles for transfer of the cytotoxic agent, 16, 19 both the CD/5-FC and NTR/CB1954 combinations have been shown to result in cell permeable toxic metabolites of the prodrug. 21, 29 An unexplained result was our finding that Jijoye cells transiently transfected with the pREP9-NTR vector induced more bystander killing than Jijoye cells stably transfected with this vector, even though a similar amount of NTR activity (per microgram of cell extract) was observed in each case. The reduced bystander killing in the stably selected cell line may indicate that a specific level of cellular NTR activity is required to efficiently reduce the CB1954 prodrug. Transient transfection (as opposed to stable selection) presumably induces a higher level of NTR activity per cell, even though fewer total cells express the enzyme. Alternatively, as has been shown to be the case for certain CD-transduced cells, 31 the cells stably expressing NTR may be killed by CB1954 before they have a chance to transfer the toxic metabolite to bystander cells.
Our results using the NTR/CB1954 regimen to treat lymphomas in vivo were not as good as those we obtained previously using either the CD/5-FC or HSV-TK/GCV combinations in vivo. 10 Although the stable NTR-expressing cell line used to make tumors in vivo clearly has some NTR expression (because it is 60-fold more sensitive to CB1954-induced cell killing than the parental line), it may not express the optimal level for efficient bystander killing, as discussed above. Thus, it remains possible that gene delivery vectors could induce cellular levels of NTR protein expression in vivo with a better bystander killing profile and consequently result in more efficient CB1954-induced tumor cell killing than we observed using our stable NTR cell line. In addition, because the tumors in the CB1954/NTR experiment were derived from EBV-positive Burkitt lymphoma cells, whereas the previous study examining the CD/ 5-FC and HSV-TK/GCV regimens used tumors derived from EBV-immortalized primary B cells, the results may not be directly comparable. Nevertheless, our finding that the NTR-expressing Jijoye cell line, which is quite sensitive to CB1954 toxicity in vitro, could not be cured by CB1954 in vivo (even when 100% of tumor cells were derived from this line) is disappointing and suggests that this regimen may not be particularly effective for the treatment of lymphomas in vivo.
Our in vitro and in vivo results also suggest that the NTR/CB1954 regimen has a smaller therapeutic index than the CD/5-FC combination. In B95-8 cells, significant cellular toxicity with CB1954 alone was observed even at the 10 M dose, although similar levels of toxicity were not observed until a dose of 100 M was used in Jijoye cells. In contrast, in the absence of CD gene expression, doses of Յ1000 M of 5-FC induced minimal cellular toxicity in Jijoye and B95-8 cells; however, in the presence of CD, 10 M of 5-FC killed Ͼ90% of the cells. In vivo, although we have not observed toxicity using 500 mg/kg/day of 5-FC i.p. (which cured all tumors expressing the CD gene in 100% of cells), 10 we did observe hair loss using the CB1954 dose of 20 mg/kg/day in some SCID mice. CB1954-induced toxicity in mice (except in those tissues expressing NTR as a transgene) was not observed in a previous study using 50 mg/kg/day, although in this study CB1954 was only given for 3 days, and the mice were killed shortly after CB1954 administration. 27 However, in another recently performed study in NTR-transgenic animals (expressed under a T-cell-specific promoter), mice receiving 20 mg/kg/day CB1954 for 5 days had Յ15% weight loss and mice receiving 50 mg/kg/day experienced severe multiorgan toxicity. 28 Therefore, certain mammalian cell types may be able to metabolize CB1954 into a toxic form or may be susceptible to CB1954 toxicity even when it remains unmodified. In this regard, it has been reported previously that certain human cell lines are susceptible to CB1954-induced toxicity in the absence of NTR gene expression, and it has been suggested that a human protein may be capable of reducing CB1954 in such cells. 32 In a similar study published after submission of this manuscript, the combination of NTR expression and CB1954 administration was recently found to increase the median survival of mice with pancreatic carcinomas in vivo. 33 Our results now indicate that the NTR/CB1954 combination also induces cell killing of EBV-positive B cells and could potentially be useful (under the control of EBV-specific promoter or replication elements) for the treatment of EBV-associated malignancies. For optimal chance of tumor cure, it may be preferable to combine a suicide/prodrug strategy that kills dividing cells (such as the CD/5-FC combination) with a strategy (such as the NTR/CB1954 combination) that can also kill nondividing tumor cells. However, our results suggest that CB1954 may be somewhat toxic even in the absence of NTR gene expression; therefore more in vivo studies are certainly required before this regimen can be recommended for the treatment of human cancers. It will also be of interest to determine whether other recently described suicide gene therapy strategies that produce diffusible cytotoxic alkylating agents 34 -38 can efficiently kill lymphoma cells in vivo.
